Sanaregen™ Vision Therapeutics Receives FDA Clearance for Clinical Trial to Treat Retinal Degeneration

NASHVILLE, Tenn.--(BUSINESS WIRE)-- #ClinicalTrials--Sanaregen Vision Therapeutics, a clinical-stage regenerative medicine company, today announced clearance by the U.S. Food and Drug Administration to conduct a Phase I/II clinical trial for SVT-001, its investigational cell therapy. The trial will assess safety and effectiveness of SVT-001 to improve retinal function and restore vision in individuals with Familial Drusen, an inherited form of macular degeneration. There are currently no approved disease-modifyi